Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

New biomarker predicts therapy response for hard-to-treat childhood cancers

A study by researchers at the University of Birmingham has identified a new biomarker for response to a specific cancer therapy, treating children with Ewing Sarcoma and other tumor types.

22 May 2026

Sequential TACE after SBRT improves outcomes in recurrent hepatocellular carcinoma

Comparative data on sequential transarterial chemoembolization (TACE) after stereotactic body radiation therapy (SBRT) in recurrent hepatocellular carcinoma (HCC) remain limited. This study aimed to evaluate the efficacy of this combination.

13 May 2026

Adult weight gain strongly linked to higher obesity-related cancer risk

New research presented at this year's European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12-15 May) shows that people who gain the highest amount of weight across adulthood are at greatly increased risk of certain obesity related cancers.

13 May 2026

New mRNA adjuvant dramatically boosts T-cell vaccine responses in mice

MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines - an advance that could lead to much more powerful cancer vaccines and stronger protection against infectious diseases.

13 May 2026

Medical imaging could improve precision diagnosis of aggressive head and neck tumors

Medical imaging routinely used in cancer care may hold far more biological information than previously thought.

13 May 2026

Implantable cytokine factories show promise against advanced ovarian cancer

Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step toward clinical reality.

12 May 2026

Tumor splicing burden predicts treatment response in kidney cancer

Researchers at City of Hope® and TGen (part of City of Hope) have identified a significant correlation between a tumor's "splicing burden" and its clinical response to treatment for metastatic renal cell carcinoma (mRCC).

5 May 2026

WHO report shows measurable progress in reducing global hepatitis infections

Global efforts to combat viral hepatitis are delivering measurable progress in reducing infections and deaths, but the disease remains a major global health challenge, according to a new World Health Organization (WHO) report released today at the World Hepatitis Summit.

28 Apr 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

Study identifies key risk factors driving MASLD across populations

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population.

23 Apr 2026

Bioengineered chewing gum reduces cancer-linked oral microbes

Researchers led by Henry Daniell of the School of Dental Medicine have shown that extracts from bioengineered chewing gum reduce the levels of three microbes known to be associated with head and neck squamous cell cancer (HNSCC), paving the way for more effective and affordable therapies.

23 Apr 2026

New "plug-and-play" AI outperforms pathologists in lymph node metastasis detection

A research team led by The Hong Kong University of Science and Technology (HKUST) has developed a pioneering artificial intelligence (AI) pathology analysis system that can accurately recognize multiple types of cancer using only a minimal number of samples-without requiring any additional training. This breakthrough significantly enhances the flexibility and efficiency of AI-assisted medical care, marking a major step forward toward the widespread adoption of intelligent pathology.

22 Apr 2026

AI model predicts immunotherapy response in lung cancer patients

A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026

AGA update calls for better surveillance of hepatocellular carcinoma

A new update from the American Gastroenterological Association (AGA) urges stronger prevention efforts and better early-detection tools for hepatocellular carcinoma (HCC), the leading cause of cancer-related death in patients with cirrhosis, and the third most common cause of cancer-related death worldwide.

17 Apr 2026

New roadmap links liver cancer biology to immunotherapy and precision medicine

A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the deadliest cancers worldwide.

17 Apr 2026

Liver cancer burden rising globally amid shift to metabolic risks

Primary liver cancer continues to pose a major global health challenge, ranking as the third leading cause of cancer-related deaths worldwide.

15 Apr 2026

Letrozole monotherapy falls short in ovarian cancer clinical trial

Late breaking results from the phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate non inferiority to paclitaxel/carboplatin followed by letrozole (PC/L) for progression free survival (PFS) in patients with newly diagnosed stage II-IV low grade serous carcinoma of the ovary or peritoneum.

11 Apr 2026

Pseudogene lncRNAs regulate cancer stem cell behavior and signaling

Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, and resistance to therapy due to their innate capacity for self-renewal and differentiation.

11 Apr 2026

Sylvester Comprehensive Cancer Center opens new trial for neuroendocrine tumors

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Apr 2026

New dual drugs eliminate tumors when combined with immunotherapy

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be "master regulators" of cancer progression.

2 Apr 2026